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ABSTRACT
Introduction Fatigue is the most commonly reported 
symptom of the liver disease primary biliary cholangitis 
(PBC). It affects 40%–80% of patients, has no effective 
treatment and is associated with heightened mortality risk. 
The pathogenesis is unknown, but muscle bioenergetic 
abnormalities have been proposed to contribute. Directly 
observed exercise has been shown to attenuate symptoms 
in small groups; however, due to the rare nature of the 
disease, home- based interventions need to be evaluated 
for feasibility, safety and efficacy.
Methods and analysis This is a phase 1/pilot, single- 
arm, open- label clinical trial evaluating a novel home- 
based exercise programme in patients with PBC with 
severe fatigue. Forty patients with moderate- severe 
fatigue (PBC40 fatigue domain score >33; other causes 
of fatigue excluded) will be selected using a convenience 
sampling method. A 12- week home- based exercise 
programme, consisting of individualised resistance, 
aerobic exercises and telephone health calls (first 6 
weeks only), will be delivered. Measures of fatigue (PBC40 
fatigue domain; fatigue impact scale), quality of life, 
sleep (Epworth Sleep Score), physical activity, anxiety and 
depression, aerobic exercise capacity (incremental shuttle 
walk test; Duke Activity Status Index) and functional 
capacity (short physical performance battery) will be 
assessed at baseline and at 6 and 12 weeks following the 
intervention.
Ethics and dissemination The protocol is approved by 
the National Research Ethics Service Committee London 
(IRAS 253115). Recruitment commenced in April 2019 and 
ended in March 2020. Participant follow- up is due to finish 
by December 2020. Findings will be disseminated through 
peer- reviewed publication, conference presentation and 
social media.
Trial registration number NCT04265235.
INTRODUCTION
Primary biliary cholangitis (PBC) is a chronic, 
immune- mediated liver disease characterised 
by progressive reduction in bile flow 
(cholestasis) that leads to biliary fibrosis and 
eventual cirrhosis.1 The exact disease mech-
anisms are unknown but considered multi-
factorial, encompassing inherited traits and 
ill- defined environmental factors.2 Incident 
rates suggest c35 per 100 000 individuals are 
affected with PBC, of whom 90% are women 
aged between 30 and 65 years at the time of 
diagnosis.3
Debilitating, refractory fatigue is one of 
the most commonly reported symptoms, 
affecting between 40% and 80% of patients.4 
Although not an indicator of liver disease 
severity, fatigue is pronounced among indi-
viduals of young presenting age and is associ-
ated with worse liver transplant- free survival, 
reduced physical activity and poorer quality 
of life (QoL) for patients. While a consensus 
biological explanation is lacking, preclin-
ical data have identified central and periph-
eral components, alongside suppressed 
anaerobic threshold during physical exer-
tion.5 6 Notably, patients with PBC suffering 
from fatigue report that it is not a single 
episode of activity they find difficult, rather 
the incapacity to perform exercise over a 
sustained period of time. This relates to 
excessive acidosis building up in peripheral 
muscle coupled with delayed pH recovery, 
which tends to manifest after only a minimal 
duration of physical exertion, compared 
with non- fatigued patients with PBC and 
healthy control subjects.5 7 Importantly, this 
pathology can be reversed through repeated 
single exercise episodes, suggesting that the 
capacity to improve muscle bioenergetics 
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is retained.5 Most strikingly, supervised graded exercise 
intervention demonstrates significant and quantifiable 
improvements in fatigue severity, together with symptom 
reduction in domains related to emotional and social 
dysfunction.5
While patients with liver disease report positive attitudes 
towards the benefits of supervised exercise, they admit 
to lack of confidence were they to initiate such activity 
themselves.5 8 Moreover, those living with fatigue have 
a natural inclination towards decreased levels of phys-
ical activity in response to symptoms.9 Similar to other 
chronic diseases, individuals are more likely to disen-
gage, become socially isolated and increase sedentary 
living due to fear of exacerbating fatigue if correct guid-
ance is not provided.10 The resulting physical inactivity is 
a catalyst for muscular degeneration, with reduced exer-
cise tolerance and functional capacity, thereby increasing 
fatigability.9 10 This ‘fatigability’ further exacerbates fear 
and sedentary living, leading to a vicious cycle of debili-
tating decline.9 The consequence of this is further phys-
ical inactivity and muscular degeneration, a reduction in 
oxygen- handling (oxygen consumption peak) and func-
tional capacity, and subsequently the speed at which the 
muscle fatigues.9–11
Access to healthcare professionals appears to reduce 
self- reported fatigue and positively influence the attitudes 
towards exercise and the long- term benefits on overall 
QoL.12–14 Moreover, home- based exercise programmes 
(HBEPs) performed at moderate intensity (rate of 
perceived exertion (RPE) 12–14) have been shown to be 
safe and improve functional capacity in patients with end- 
stage liver disease.15 However, there are no studies that 
explore the feasibility and efficacy of a moderate- intensity 
HBEP on improving fatigue or functional capacity in 
patients with PBC.
Prior to performing a dedicated randomised controlled 
trial (RCT), a pilot feasibility study is required to 
determine whether intervention can be conducted within 
patients’ homes, determine whether a larger programme 
is possible and highlight preferential design features. To 
this effect, our aim is to conduct a single- centre trial of 
a structured HBEP, which attenuates fatigue associated 
with PBC. Efficacy assessment will be through validated 
health- related quality of life (HRQoL) measures, and 
fatigue- specific and functionality assessment tools.
METHODS AND ANALYSIS
Study design overview
This is a single- arm, single- centre feasibility trial of a 
graded HBEP for the treatment of chronic fatigue in 
patients with PBC. Patients will be recruited through the 
Liver Unit based at the University Hospitals Birmingham 
(UHB) National Health Service (NHS) Foundation Trust, 
UK. An individualised, graded HBEP will be delivered for 
12 weeks to investigate safety, adherence and treatment 
efficacy (figure 1). Fatigue, HRQoL, functional capacity 
and sleep quality will be recorded at baseline and at 6 and 
12 weeks following initial assessment.
Sample and selection
Patients attending the dedicated PBC clinic will be 
presented with a PBC40 questionnaire, which is a robustly 
validated HRQoL measure specifically for application in 
PBC.16 Given that some patients experience fatigue by 
virtue of having advanced disease, our study will exclu-
sively target individuals who have clinically significant 
symptoms although with fully compensated liver func-
tion. Patients with clinically significant fatigue (defined 
by a PBC40 fatigue domain score >33) will be asked to 
complete a second questionnaire remotely, 14 days after 
initial assessment.16 17 Patients with persistently elevated 
scores (in the absence of other contributory causes) will 
Figure 1 Study overview. Patients with moderate- severe fatigue (PBC40 fatigue domain score >33) will be identified from 
clinic and PBC40 fatigue assessment completed. Eligible participants will be invited to attend a dedicated screening visit 
within 2 weeks and a repeat PBC40 questionnaire completed. After obtaining consent, the investigator will perform full 
physical and symptom assessment of the trial participant and demonstrate the intended intervention. The trial participant will 
then be observed while performing the aforementioned intervention and will be provided a symptom diary and single- blinded 
GeneActiv accelerometer for home use (daily activity monitor readings will be captured remotely by the investigator, but not 
visible by the participant). Thereafter, the participant will be instructed to perform a tailored, daily HBEP by the investigators 
(liver physiotherapist and personal trainer). Weekly telephone support will be provided in the first 6 weeks (interval between visit 
1 and visit 2), together with modifications to the exercise programme as needed. At week 6, the trial participant will be invited 
for an interim assessment, followed by another 6 weeks of intervention. Weekly telephone support will be withdrawn between 
weeks 6 and 12 (end of the study). Assessment of the primary efficacy measure will be performed at week 12 (end of study 
visit). HBEP, home- based exercise programme; PBC, primary biliary cholangitis; PIS, patient information sheet.
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be deemed eligible for trial participation. Additional 
criteria for trial entry include the following.
Inclusion criteria
 ► ≥ 18 years old.
 ► A confirmed diagnosis of PBC, in keeping with inter-
national guidelines.18
Exclusion criteria
 ► Decompensated liver disease, as evident by the pres-
ence of ascites, hepatic encephalopathy (any grade) 
and history of variceal bleeding.
 ► Total bilirubin of >50 μmol/L, in the absence of 
Gilbert’s syndrome.
 ► Prior liver transplantation.
 ► On the waitlist for or likely to need referral for liver 
transplantation in the next 6 months (judged by the 
principal investigator (PI)).
 ► Refractory pruritus (judged by the PI).
 ► No dual- energy X- ray absorptiometry scan within 5 
years.
 ► Untreated osteoporosis.
 ► Cardiovascular instability (judged by PI).
 ► Untreated hypovitaminosis or anaemia.
 ► Untreated hypothyroidism.
 ► Untreated coeliac disease.
 ► WHO performance status ≥3.
 ► History of unexplained falls.
 ► Neither patient nor next of kin are English speaking.
 ► Refusal or lack of capacity to give informed consent.
 ► Participation in another interventional trial for PBC 
in the last 3 months.
 ► Concomitant excess alcohol consumption (>14 units 
for women; >21 for men).
 ► Concomitant liver disease of another aetiology, 
including (but not limited to) viral hepatitis, auto-
immune hepatitis, primary sclerosing cholangitis, 
alcohol- induced liver disease, non- alcoholic fatty liver 
disease, Wilson disease, alpha-1- antitrypsin deficiency, 
Budd- Chiari syndrome, hereditary haemochroma-
tosis, drug- induced liver injury and IgG4- related 
disease.
 ► Intercurrent active or latent infection.
 ► Intercurrent immunocompromised state.
 ► Concurrent chemotherapy.
 ► Active malignancy (other than non- melanomatous 
skin cancer).
Once screened and deemed eligible, patients will be 
contacted via telephone to discuss their involvement 
within the study, and a patient information sheet will sent 
sent by the chief investigator (CI) or co- investigator (Co- 
I). If individuals agree to take part, an appointment will 
be arranged for written consent, baseline assessment and 
an initial supervised exercise session.
Study visits
Patients who suffer from PBC attend regular clinic 
appointments as part of routine clinical care. Where 
possible, all study visits will be conducted on the same 
day as routine clinic appointments to reduce the burden 
of hospital attendance and travel.
The study requires three separate attendances to the 
clinic: at week 0 (visit 1—baseline), week 6 (visit 2) and 
week 12 (visit 3—end of study) (figure 1). At each visit, 
the assessment of fatigue, HRQoL, functional capacity 
and sleep quality will be quantified.
Visit 1
At week 0 (baseline), fatigue will be quantified using the 
PBC40 fatigue domain and Fatigue Impact Scale (FIS).19 
Additional metrics recorded at baseline will include the 
following:
 ► Remaining components of the PBC40 assessment 
tool.16
 ► The Chronic Liver Disease Questionnaire (CLDQ).20
 ► The Hospital Anxiety and Depression Scale (HADS)21
 ► The Epworth Sleep Score (ESS).22
 ► Measures of functional and aerobic capacity:
 – Incremental shuttle walking test (ISWT).23 24
 – Short performance physical battery (SPPB).25
 – Duke Activity Status Index (DASI).26
Baseline assessment will also capture anthropometric 
data (age, sex, weight, height and body mass index), 
details of PBC- specific treatments (including ursode-
oxycholic acid (UDCA), obeticholic acid, fibric acid 
derivatives, bile acid sequestrants, rifampicin, selective 
serotonin reuptake antagonists, opioid antagonists), 
dietetic input (eg, use of protein supplements) and labo-
ratory data (liver biochemistry, renal function, thyroid 
function, vitamin D levels, haemoglobin A1c, full blood 
count and clotting profile).
Intervention and monitoring
Participants will be provided with a moderate- intensity, 
low- impact individualised HBEP dependent on index 
measures of physical activity, performance status and 
confidence with intervention during visit 1. Participants 
will be advised to exercise within a Borg RPE of 12–14, as 
this has been shown to correlate with anaerobic thresholds 
in healthy individuals and improve functional capacity in 
patients with end- stage liver disease.15 27 In addition, each 
participant will be given a GENEActiv wrist accelerometer 
in a single- blind manner (which will provide retrospec-
tive feedback on activity to the investigators but not the 
participants) to wear 24 hours a day during the 12- week 
study period. The GENEActiv will encompass assessment 
of physical activity and sleep quality. In parallel, a paper- 
based patient diary will be provided to record HBEP 
targets, alongside a copy of their specific programme.15
Home-based exercise program
Following discussions with our patient and public involve-
ment group, it was recommended that all interven-
tions should include functional movements, require no 
specialist equipment, that exercise instructions should 
be supported with written information and the overall 
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commitment should not involve more than three sessions 
per week. Therefore, at initial assessment, participants 
will be taught functional resistance exercises that they 
can complete at home (table 1 and online supplemental 
appendix 1)—as previously described.15 Entry levels will 
be determined depending on individual physical capacity 
and confidence. Each participant will be observed 
completing their specific exercise programme during visit 
1, under the supervision of an accredited specialist phys-
iotherapist and a qualified personal trainer. Patient tech-
nique, safety and confidence in completing each exercise 
will be assessed, as well as ensuring they can maintain an 
RPE of 12–14 throughout the exercise session. Partici-
pants will be advised to complete functional resistance 
exercises 2–3 times per week (depending on capability) 
as this has been shown to correlate with physiological 
change and will be provided with written information for 
each exercise to guide completion at home. Although 
patients will not be directly supervised while conducting 
exercises at home, remote monitoring through assess-
ment of accelerometer data and weekly telephone calls 
will be conducted during this time.15
The RPE is a psychophysical tool that is widely used to 
assess the perception of effort during exercise across a 
multitude of health conditions and positively correlates 
with both heart rate and blood lactate.27 Given its 
simplicity, acceptance within healthcare and assurance 
that it correlates with physiological change, the use of 
RPE during execution of the field test and HBEP was 
deemed an appropriate choice. This will also allow for 
an individualised approach and inclusivity of participants 
despite baseline functional ability. Supplementary tele-
phone calls will allow for remote progression and regres-
sion of exercises and monitoring of adverse symptoms 
including exertion- related chest discomfort, light head-
edness or dizziness.
At the week 6 assessment, the programme will be 
reviewed and amended (where appropriate) according 
to participants’ functional/aerobic capacity and confi-
dence (table 1 and online supplemental appendix 1).
Between visit 1 and visit 2
Weekly targets and progressions or regressions will be 
facilitated by supplementary telephone calls from week 0 
to week 6.15 These will be delivered by the physiotherapist 
to provide remote monitoring and support regarding the 
HBEP. The focus will be to:
 ► Assess compliance to the study intervention.
 ► Discuss the severity of fatigue.
 ► Discuss adverse effects that have not been reported 
in the interval prior to last communication with the 
patient.
 ► Review of exercises to give patients an opportunity to 
discuss any concerns or ask questions related to the 
exercise programme.
 ► Determine the need for progression or regression of 
the HBEP, including any individualised modifications 
that need to be made. For instance, modifications will 
be made if participants find a particular exercise too 
difficult (or easy) or are not reaching training zones 
of a self- reported RPE of 12–14. The activity time can 
also be increased and rest phase decreased, in the 
event participants report the programme to not be 
challenging enough (and vice versa).
Following the week 6 assessment (visit 2), telephone 
support will be withdrawn to assess long- term adherence 
to the study intervention.
Visit 2
At week 6 after the intervention, participants will be 
invited back to re- evaluate all baseline functional/aerobic 
capacity tests, HRQoL scores, and symptom severity and 
ensure appropriate adjustments to the HBEP are made.
Visit 3
The intervention will conclude at week 12, at which point 
investigators will assess all aforementioned parameters a 
final time. Participant diaries and accelerometers will be 
collected at this point.
Project objectives
 ► Determine whether HBEP intervention is feasible 
and safe.
 ► Identify whether HBEP attenuates fatigue in patients 
with PBC.
 ► Outline the longevity in improvement in symptoms 
of fatigue and HRQoL once health- related telephone 
support is withdrawn.
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Outcome measures
The overarching goal of this study is to determine the 
feasibility of HBEP among patients with PBC with clini-
cally significant fatigue, with the decision to proceed to a 
subsequent RCT made on the following criteria:
 ► Sample size: >25% of sample population (ie, patients 
with PBC and fatigue) eligible for study.
 ► Patient consent: >66% of eligible study population 
consented to the study.
 ► Safety: No severe adverse effects related to the study 
intervention.
 ► Adherence: >80% adherence with HBEP for a 
minimum of 6 weeks (measured by self- reported 
diaries).
Our primary efficacy measure will be a reduction in 
median fatigue severity score according to the PBC40 
QoL assessment tool. The PBC40 HRQoL assessment 
tool has been developed and extensively validated for use 
among patients with PBC, with the fatigue domain being 
the most commonly applied measure of treatment effi-
cacy used in clinical trials.16–18
Secondary measures of efficacy will be gauged by 
changes in the following assessment tools, and justi-
fication for use can be found in online supplemental 
appendix 2:
 ► FIS.19
 ► The other domains of the PBC40 QoL tool, relating 








 ► Liver biochemical parameters, namely, serum alka-
line phosphatase, bilirubin and alanine transaminase.
 ► GENEActiv physical activity and sleep quality.
Additional exploratory analysis will be conducted to 
study associations between fatigue and baseline patient 
demographics, seasonality and underlying UDCA 
response status, alongside the other domains of the 
PBC40 questionnaire.
Data capture
All qualitative and quantitative data will be entered into 
a purposely designed, secure access database and data 
subsequently analysed (SPSS V.24; IBM). Feasibility deci-
sion rules and clinical outcome measures will be presented 
using descriptive statistics. Quantitative changes before 
and after the intervention (from baseline to week 6 and 
to week 12) will be tested using a non- parametric statis-
tical hypothesis for repeated measurements (Wilcoxon 
signed- rank test).
Adverse events
There will be a strict process for reporting adverse events 
(AEs) and adverse reactions (ARs), which will commence 
at screening and continue until the final participant has 
completed study intervention. All AEs, serious AEs (SAEs), 
ARs and serious unexpected ARs will be reported to the 
CI and sponsor’s research and development department 
via a dedicated case report form (CRF). Only AEs or SAEs 
that can be deemed probable or absolutely related to the 
study will be reported to the Research Ethics Committee.
Storage of data
All data relating to the study will be collected by the Co- I 
and recorded in standardised CRFs. Each participant will 
be given a unique study number at the time of consent 
and used as a way of identification. Data will be collected 
from the participant at point of entry into the study until 
completion of the intervention. All clinical data will be 
stored securely as per NHS regulations for a minimum of 
15 years. All data documented on the CRF will be entered 
into an NHS password- secured computer and in concor-
dance with the Data Protection Act 1998. All essential 
written documentation will be stored in line with the 
appropriate regulatory requirements and restricted to 
researchers essential to the study. Coded research data 
will be stored for 5 years anonymously under the prop-
erty of the Queen Elizabeth Hospital UHB in keeping 
with good clinical practice.
Case report forms
CRFs will be completed at week 0 (baseline), week 6 
and week 12 (end of study), and include all question-
naire and functional outcomes. Electronic CRFs will be 
completed on an NHS Trust password protected system 
and will include medical history, eligibility screening and 
study treatment adherence.
Sponsorship, indemnity and monitoring
UHB will act as sponsor for the duration of the study. As 
sponsor, UHB will be responsible for the conduct of the 
study and indemnify the study centre against any claims, 
arising from any negligent act or omission by the hospital 
in fulfilling the sponsor role in respect to the study. The 
study is supported by an unrestricted grant from Inter-
cept Pharmaceuticals
DISCUSSION
This is the first feasibility trial investigating HBEP in 
the treatment of refractory fatigue and QoL in patients 
with PBC. To date, 262 individuals with PBC have been 
preidentified, of whom 82 are deemed eligible, and 42 
agreed to attend a dedicated screening visit.
Safety
Supervised exercise sessions and advice are well supported 
within chronic disease, but there are very few that focus 
on home- based exercise and how this influences fatigue. 
Moreover, there are a limited number of large RCTs 
that report safe use of exercise therapy in patients with 
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Combined with education and the chosen objective 
measures, participants will have clear training guidelines 
and supporting information along with contact numbers 
to reduce the risk of AEs. With supplementary weekly 
telephone calls across the first 6 weeks, the opportunity to 
discuss any concerns or AEs will be available.26 Rigorous 
exclusion criteria will help to reduce the risk of AEs and 
maximise the safety of remote exercise intervention that 
is monitored via health telephone calls. This will allow 
for maximal participation while ensuring a safe exercise 
regimen is followed.
The intervention itself has been developed and 
based on well- documented moderate- intensity 
training models and extrapolated from an exercise 
protocol, which demonstrated the safety of such a 
HBEP in patients with more advanced liver injury.15
Challenges to study design
One in 5000 individuals are affected by PBC, with 
>90% of those being women aged between 30 and 
65 years.3 Consequently, many eligible participants 
are in some form of employment and have family 
responsibilities. This will need to be considered when 
recruiting to the study, and where possible, ensure 
that research- related visits link with clinic visits to 
reduce participant burden.
As the study intervention is predominantly home- 
based, education and support to aid adherence 
are fundamental. Although it is well recorded that 
debilitating fatigue and its impact on HRQoL is the 
most widely reported symptom of PBC, very little is 
understood about individual influences. To aid in the 
assessment of adherence, participants will be asked 
to complete a study diary, with the aim of tracking 
self- reported physical activity and providing aggre-
gate data in relation to weekly targets. Participants 
will also receive written information and pictures of 
their individualised exercise programme, with an 
opportunity to record exercises digitally. The inter-
vention itself has been developed and based on well- 
characterised moderate- intensity training models and 
extrapolated from an exercise protocol that demon-
strated the safety of HBEP among patients with more 
advanced liver injury.15
As fatigue differs greatly between individuals, the 
study intervention needs to offer a variety of exer-
cises that can be progressed and regressed while 
still improving functional/aerobic capacity. Multiple 
intensity levels offer a unique approach as have 
been designed to help ensure the interventions were 
individually targeted with the flexibility to adapt if 
needed.
Future RCT considerations
This phase 1, single- centred feasibility study is required 
not only to demonstrate the safety of the intervention 
but also to highlight recruitment, dropout rates and 
adherence. Without this information, it would not be 
possible to power the correct number of participants 
needed for future RCTs.
Summary
To the best of our knowledge this is the first study 
to investigate HBEP in patients with PBC with debil-
itating fatigue. Enrolment for participation in the 
study is completed, and final results are expected in 
early 2021.
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